ZOETIS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 158.4 USD | +3.30% |
|
+8.14% | -19.73% |
| 04-23 | Barclays Adjusts Zoetis' Price Target to $230 From $260, Keeps Overweight Rating | MT |
| 04-22 | Jefferies Lowers Zoetis Price Target to $200 from $220 | MT |
ETFs positioned on Zoetis Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.87% | 1 M€ | -.--% | ||
| 3.35% | 18 M€ | +3.79% | - | |
| 2.04% | 36 M€ | -.--% | ||
| 2.01% | 115 M€ | +5.90% | - | |
| 1.75% | 4,592 M€ | +11.18% | ||
| 1.44% | 10 M€ | +6.14% | - | |
| 1.35% | 1 M€ | +8.00% | - | |
| 1.00% | 9 M€ | -.--% | - | |
| 0.88% | 2 M€ | +20.44% | - | |
| 0.82% | 469 M€ | -2.05% | - | |
| 0.82% | 3,859 M€ | +18.82% | - | |
| 0.77% | 282 M€ | +3.59% | - | |
| 0.67% | 92 M€ | +0.06% | - | |
| 0.65% | 5 M€ | -72.95% | - | |
| 0.54% | 267 M€ | +5.99% | ||
| 0.53% | 322 M€ | +13.88% | - | |
| 0.53% | 29 M€ | -.--% | - | |
| 0.52% | 1,006 M€ | -.--% | - | |
| 0.52% | 414 M€ | +10.21% | - | |
| 0.49% | 2 M€ | +21.73% | - | |
| 0.48% | 1,448 M€ | -.--% | - | |
| 0.48% | 219 M€ | +17.17% | - | |
| 0.44% | 2,510 M€ | +12.00% | ||
| 0.44% | 330 M€ | -.--% | - | |
| 0.44% | 2 M€ | +14.69% | - | |
| 0.40% | 2 M€ | +6.77% |
Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:
- pets (64.4%): cats and dogs (94.9% of net sales) and horses (5.1%);
- livestock (34.5%): cattle (51.6% of sales), swine (20.2%), poultry (17.1%), fish (7.6%) and other (3.5%);
- other (1.1%).
Net sales break down by family of products into parasiticides (23%), vaccines (21.3%), dermatological products (16.4%), anti-infectives (13.4%), medical food additives (4.5%), diagnostic products (4.4%) and other (17%).
At the end of 2022, the group has 29 production sites worldwide.
The United States accounts for 53.4% of net sales.
Sector
Pharmaceuticals
Calendar
02/05/2024
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
158.4
USD
Average target price
215.2
USD
Spread / Average Target
+35.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -2.92% | 3.12B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -2.73% | 1.26B | |
| -14.67% | 1.12B | |
| -5.37% | 990M | |
| -24.06% | 805M |
- Stock Market
- Equities
- ZTS Stock
- Funds and ETFs Zoetis Inc.
